Cancer treatment – Parentraide Cancer http://parentraide-cancer.org/ Sun, 19 Sep 2021 01:22:01 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://parentraide-cancer.org/wp-content/uploads/2021/06/icon.png Cancer treatment – Parentraide Cancer http://parentraide-cancer.org/ 32 32 Enzalutamide Plus ADT prolongs survival in metastatic hormone-sensitive prostate cancer https://parentraide-cancer.org/enzalutamide-plus-adt-prolongs-survival-in-metastatic-hormone-sensitive-prostate-cancer/ https://parentraide-cancer.org/enzalutamide-plus-adt-prolongs-survival-in-metastatic-hormone-sensitive-prostate-cancer/#respond Sun, 19 Sep 2021 00:00:00 +0000 https://parentraide-cancer.org/enzalutamide-plus-adt-prolongs-survival-in-metastatic-hormone-sensitive-prostate-cancer/ Combination of enzalutamide with androgen deprivation therapy (ADT) provides long-term survival benefit, compared to ADT alone, in patients with metastatic hormone-sensitive prostate cancer (mHSPC ), based on the final results of the ARCHES Phase 3 trial.1 These results were presented at the 2021 Congress of the European Society for Medical Oncology (ESMO) by Andrew J. […]]]>

Combination of enzalutamide with androgen deprivation therapy (ADT) provides long-term survival benefit, compared to ADT alone, in patients with metastatic hormone-sensitive prostate cancer (mHSPC ), based on the final results of the ARCHES Phase 3 trial.1

These results were presented at the 2021 Congress of the European Society for Medical Oncology (ESMO) by Andrew J. Armstrong, MD, of the Duke Cancer Institute Center for Prostate & Urologic Cancers in Durham, North Carolina.


Read on

Dr Armstrong noted that enzalutamide plus ADT has been approved for the treatment of mHSPC in the United States and Europe based on previous results from the ARCHES trial (ClinicalTrials.gov Identifier: NCT02677896).

The phase 3 trial enrolled 1150 men with mHSPC. They were randomized 1: 1 to receive enzalutamide plus ADT (574 patients) or placebo plus ADT (576 patients) and were stratified by volume of disease and previous treatment with docetaxel.

In the primary analysis, enzalutamide plus ADT reduced the risk of radiographic disease progression by 61% (P <.001) and improved key secondary endpoints, but overall survival (OS) data were immature at that time.2

Based on the results of the main analysis, the study was blinded to allow crossbreeding. A total of 180 patients (31.3%) in the placebo arm were crossed over to receive enzalutamide plus ADT. The median time to cross was 21.5 months.

During ESMO 2021, Dr. Armstrong reported the results as of May 28, 2021. At this point, there have been 356 deaths – 154 in the enzalutamide arm and 202 in the placebo arm.

The median follow-up was 44.6 months. The median duration of treatment was 40.2 months in the enzalutamide arm, 13.8 months in the placebo arm and 23.9 months for the crossover patients.

Dr. Armstrong reported that patients in the enzalutamide arm had a significant delay in the need for subsequent antineoplastic therapy. The median time to subsequent treatment was not reached in the enzalutamide arm and was 40.5 months in the placebo arm (hazard ratio [HR], 0.38; 95% CI: 0.31-0.48).

Median OS was not achieved in any of the arms, but enzalutamide plus ADT significantly improved OS by 34% compared to placebo plus ADT (RR: 0.66; 95% CI: 0.53 -0.81; P <.0001). At 4 years, the OS rate was 71% in the enzalutamide arm and 57% in the placebo arm.

The benefit of OS with enzalutamide was maintained regardless of disease volume, previous local treatment, disease location, Gleason score, initial prostate specific antigen level, condition functional, age and geography.

“The survival benefit does not appear to be related to differential reception of subsequent antineoplastic treatments, and the survival benefit has been observed despite the fact that 70% of patients on placebo have received life-prolonging treatment to date … , 40% of whom received enzalutamide, “said Dr. Armstrong. mentioned.

He added that the safety results of the final scan are consistent with the results of the primary scan.

There was no treatment-related fatal adverse event (AE) in the enzalutamide arm, but there was 1 in the placebo arm. More patients in the enzalutamide arm than in the placebo arm had to discontinue study treatment due to AEs – 13.8% and 5.6%, respectively.

Disclosures: This research was supported by Astellas Pharma and Pfizer. Some study authors reported affiliations with biotech, pharmaceutical and / or device companies. Please see the original reference for a full list of disclosures.

To learn more about Cancer Therapy Advisor’s ESMO 2021 coverage, visit the conference page.

The references

  1. Armstrong AJ, Iguchi T, Azad AA, et al. ARCHES Final Overall Survival (OS) Analysis: Phase 3, randomized, double-blind, placebo-controlled (PBO) study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with hormone-sensitive metastatic prostate cancer (mHSPC)). Presented at: 2021 Congress of the European Society of Medical Oncology (ESMO); September 16-21, 2021. Summary LBA25.
  2. Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. ARCHES: A randomized phase III study of androgen deprivation therapy with enzalutamide or placebo in men with hormone-sensitive metastatic prostate cancer. J Clin Oncol. 2019; 37 (32): 2974-2986. doi: 10.1200 / JCO.19.00799


Source link

]]>
https://parentraide-cancer.org/enzalutamide-plus-adt-prolongs-survival-in-metastatic-hormone-sensitive-prostate-cancer/feed/ 0
Phase 3 data reinforces role of cemiplimab in second-line treatment of cervical cancer https://parentraide-cancer.org/phase-3-data-reinforces-role-of-cemiplimab-in-second-line-treatment-of-cervical-cancer/ https://parentraide-cancer.org/phase-3-data-reinforces-role-of-cemiplimab-in-second-line-treatment-of-cervical-cancer/#respond Sat, 18 Sep 2021 13:16:57 +0000 https://parentraide-cancer.org/phase-3-data-reinforces-role-of-cemiplimab-in-second-line-treatment-of-cervical-cancer/ In May, results showed that cemiplimab (Libtayo, Regeneron / Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression. In 2018, presenters from the American Society of Clinical Oncology (ASCO) turned heads by saying they were heading straight for a Phase 3 cervical […]]]>

In May, results showed that cemiplimab (Libtayo, Regeneron / Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.

In 2018, presenters from the American Society of Clinical Oncology (ASCO) turned heads by saying they were heading straight for a Phase 3 cervical cancer trial with the point inhibitor. cemiplimab control, based on responses from 2 of 3 patients in a phase 1 dose escalation trial.1

The results of just 3 patients led to the largest ever trial of patients with unmet need in cervical cancer: those with recurrent or metastatic disease who had previously been treated with chemotherapy at the cervix. platinum base. The investigators, led by Krishnansu S. Tewari, MD, professor and director of the Division of Gynecological Oncology at the University of California, Irvine, launched GOG 3016, a study by the Gynecologic Oncology Group, a non-profit organization funded by the National Cancer Institute.

Now called EMPOWER-1, the trial reported interim results at a May 2021 virtual plenary session of the European Society for Medical Oncology (ESMO), and Tewari followed up with a presentation at the virtual congress of the ESMO 2021 from September 16 to 21.2

The May results showed that cemiplimab (Libtayo, Regeneron / Sanofi) produced significant benefits: a 31% reduction in the risk of death (overall survival, OS) and a 25% reduction in the risk of disease progression ( progression-free survival, PFS). At the ESMO session on September 17, Tewari expanded on these findings and discussed their importance in the context of what women with advanced cervical cancer were facing just a few years ago.

Tewari was part of the last big breakthrough in cervical cancer, when in 2013 he was the lead author of a GOG study which showed that adding bevacizumab to chemotherapy could improve by 21% SG in advanced cervical cancer.3 But, “after that we had a bit of a drought,” he said. Commentator Rosalind Glasspool, MBBS, PhD, University of Glasgow, who appeared before Tewari, agreed.

The results of phase 3 compared 304 patients taking cemiplimab with 304 who chose the chemotherapy chosen by the investigator in second-line patients, regardless of PD-L1 expression. Patients received either 350 mg of cemiplimab intravenously every 3 weeks or chemotherapy for up to 96 weeks. The results showed the following:2

  • The median age of the patients was 51 years (range 22-87); 477 patients had squamous cell carcinoma (SCC) and 131 had adenocarcinoma (AC).
  • The median exposure to cemiplimab was 15 weeks.
  • Overall, the median OS was 12 months in the cemiplimab group and 8.5 months in the chemotherapy group, for a hazard ratio (HR) of 0.69 (0.56-0.84, P <.001).
  • In the CSC group, the median OS was 11.1 months for cemiplimab vs. 8.8 months for chemotherapy, for an RR of 0.73 (0.58-0.91, P = 0.003). In the AC group, the median OS was 13.3 months for cemiplimab vs. 7.0 months for chemotherapy, for an HR of 0.56 (0.36-0.85, P <.005).
  • While patients received benefit regardless of PD-L1 status, Tewari’s presentation showed that the benefit over chemotherapy was greater in patients with PD-L1 ≥ 1%.
  • Quality of life scores for patients taking cemiplimab were maintained or slightly improved from baseline, while scores decreased for those on chemotherapy.

Tewari said that EMPOWER-1 is distinguished by its size and the nature of the patient population, and that there have been no new safety signals. “We believe it is a drug that can be used as a second line for patients,” he said. The arrival of bevacizumab originally addressed an unmet need, “But it created a new group of patients who also had an unmet need. And these are the patients who need second-line treatment.

Glasspool had discussed several emerging issues related to the use of immunotherapy in advanced cervical cancer, including the possibilities of combination therapy, in particular anti-TIGIT treatment. Tewari said these are all great options, but it’s important to remember how quickly the field has changed.

“When Regeneron / Sanofi started the EMPOWER trial investigating the PD-1 inhibitor as monotherapy with cemiplimab versus the chemotherapy of the doctor’s choice, there was nothing more really being done. “, did he declare.

“Now the space is so crowded, and I think we’re getting more and more molecular data from these studies, and [can] better characterize who will be the exceptional responders to various therapies and who will be the bad responders, we will be able to determine where to plug all these different agents. Because I think there is room for each of them.

The references

  1. Tewari KS, Vergote I, Oaknin A, et al. GOG 3016 / ENGOT-cx9: An open-label, multinational, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator’s choice (CI) chemotherapy in cervical cancer. 2nd line recurrent or metastatic uterus. J Clin Oncol 2018; 36 (suppl; abstr TPS5600).
  2. Tewari KS, Monk BJ, Vergote I, et al. EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9: Interim analysis of the phase III trial of cemiplimab versus chemotherapy (chemotherapy) chosen by the investigator (IC) in recurrent / metastatic cervical carcinoma (R / M). Presented at the 2021 Virtual Congress of the European Society of Medical Oncology. September 16-21, 2021. Summary VP4_2021
  3. Tewari KS, Sill MW, Long HJ. Improved survival with bevacizumab in advanced cervical cancer. N English J Med. 2014; 370: 734-743. DOI: 10.1056 / NEJMoa1309748


Source link

]]>
https://parentraide-cancer.org/phase-3-data-reinforces-role-of-cemiplimab-in-second-line-treatment-of-cervical-cancer/feed/ 0
MD Anderson Research Highlights: ESMO 2021 Sp https://parentraide-cancer.org/md-anderson-research-highlights-esmo-2021-sp/ https://parentraide-cancer.org/md-anderson-research-highlights-esmo-2021-sp/#respond Sat, 18 Sep 2021 00:32:37 +0000 https://parentraide-cancer.org/md-anderson-research-highlights-esmo-2021-sp/ HOUSTON University of Texas MD Anderson Cancer CenterResearch Highlights provide an overview of recent studies in basic, translational and clinical cancer research conducted by the experts at MD Anderson. This special edition includes oral presentations by researchers from MD Anderson during the virtual conference European Society for Medical Oncology (ESMO) 2021 Congress on novel therapeutic […]]]>

HOUSTON University of Texas MD Anderson Cancer CenterResearch Highlights provide an overview of recent studies in basic, translational and clinical cancer research conducted by the experts at MD Anderson. This special edition includes oral presentations by researchers from MD Anderson during the virtual conference European Society for Medical Oncology (ESMO) 2021 Congress on novel therapeutic approaches, including cell therapy for solid tumors, antibody-drug conjugates targeting TROP2, and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.

Besides, Gabriel Hortobagyi, MD, will present the overall survival (OS) results of the MONALEESA-2 phase III trial of ribociclib and / or hormone therapy in postmenopausal patients with positive hormone receptor (HR +) receptors for human epidermal growth factor 2- metastatic (HER2-) negative breast cancer. The last minute summary (LBA-17) will be presented on Sunday, September 19 at 6.30am CST.

Anti-TROP2 drug SKB264 shows promising results for the treatment of locally advanced or metastatic solid tumors (Summary 514O)

SKB264, an antibody-drug conjugate, is composed of an antibody that targets the trophoblast cell surface antigen 2 (TROP2), which stimulates cancer growth by promoting self-renewal, proliferation, invasion and cell survival. Since TROP2 is commonly overexpressed in various types of solid tumor cancers, including breast, cervical, kidney, lung and pancreas cancers, it has become an emerging area of ​​interest as therapeutic target.

Study manager Jordi Rodon Ahnert, MD, Ph.D., will present the results of a first global human trial testing the safety, tolerability, pharmacokinetics and antitumor activity of SKB264 as monotherapy in patients with unresectable solid tumors who have not responded to treatment standard or have relapsed. Results showed that all 18 patients included in three dose levels of the trial reported treatment-occurring adverse events (TERs), the most common being grade 1-2 nausea (72.2%), decrease in the number of white blood cells (22.2%) and anemia (16.7%). The most common grade 3 or higher ADEs were decreased neutrophil count (27.8%), decreased white blood cell count (22.2%), and anemia (16.7%), but all patients recovered after receiving the corresponding treatment.

The therapy was partially responded to in six patients, two with triple negative breast cancer, two with ovarian cancer, one with HER2 + breast cancer and one with gastric adenocarcinoma. The drug had an overall response rate of 35.3% and a disease control rate of 70.6%. While the dose escalation study is still ongoing, data to date has demonstrated encouraging safety and anti-tumor activity.

New Targeted Therapy Shows Promise Against Refractory Solid Tumors Expressing Mesothelin In Dose Escalation Study (Abstract 959O)

Mesothelin is a cell surface glycoprotein that is normally found on the mesothelial cells lining the pleura, peritoneum, and pericardium. However, overexpression of this glycoprotein has been detected in various human cancers – including malignant mesothelioma, ovarian cancer, cholangiocarcinoma, and non-small cell lung cancer – making it a possible candidate for therapy. targeted.

Gavocabtagene autoleucel (gavo-cel), an anti-mesothelin T cell receptor fusion construct (TRuC), is a new cell therapy designed to recognize and destroy cancer cells by exploiting the entirety of the T cell receptor. Principal Investigator David Hong, MD, will present the data of a phase I / II escalating dose clinical trial evaluating the safety of gavo-cel either as monotherapy or following a regimen of lymphodepletion chemotherapy in patients with treatment-resistant solid tumors expressing mesothelin.

The study included 17 heavily pretreated patients who had mesothelin-expressing tumors on at least 50% of viable cancer cells and did not respond to any of the options approved by the FDA. The results showed that the toxicity profile of gavo-cel was manageable up to the maximum tolerated dose of 5×108/ m2. Of the 16 evaluable patients who were treated with gavo-cel, 15 achieved 5-75% regression of their target lesions. Four of the six patients treated with gavo-cel after lymphodepletion had a reduction of more than 50% in their tumor size and obtained a partial response, indicating that the lymphodepletion was related to higher maximal expansion and greater tumor regression. The disease control rate was 81% and the overall response rate was 25% according to an independent review and 31% for those who received gavo-cel after lymphodepletion.

The researchers plan to continue the study of gavo-cel to identify the highest dose with acceptable toxicity and to initiate phase II of the study, which will test the effectiveness of gavo-cel as a single agent and in combination with checkpoint inhibitors on different types of tumors.

Neoadjuvant immunotherapy shows potential for an organ preservation approach in some patients (Abstract 1758O)

The immune checkpoint inhibitor Pembrolizumab significantly improves clinical outcomes in patients with advanced solid tumors with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). These tumors contain defects in normal DNA repair processes, leading to a build-up of genetic mutations and the production of mutant proteins, or neo-antigens, which can be recognized as abnormal by the immune system.

Neoadjuvant, or presurgical, therapy has the potential to extend the benefits of immunotherapy earlier in treatment and save patients the need for surgical resection of affected organs. Kaysia Ludford, MD, and colleagues will present data from a phase II MD Anderson study evaluating the safety and efficacy of pembrolizumab in 35 patients with localized resectable solid tumors or at high risk MSI-H / dMMR.

Treatment was well tolerated, with grade 3-4 side effects seen in three patients, including transaminitis, diarrhea, and type 1 diabetes. At a median follow-up of nine months, the overall response rate, such as determined by imaging, was 75%, including eight complete responses and 16 partial responses. Seven patients had stable disease and one had progressive disease. Evaluation of the response by luminal endoscopy reported a complete response rate of 55% and an almost complete response rate of 18%.

After completing 12 months of pembrolizumab, four patients opted out of surgery and had no recurrence after a median follow-up of three months. Five other patients stopped treatment before one year of treatment and showed clinical benefit, including one patient with stable disease and four with partial or complete response. Of the 15 patients who chose to have surgery, 10 had a complete response. The results suggest that the neoadjuvant pembrolizumab is safe and well tolerated and that the nonsurgical management of localized MSI-H / dMMR tumors should be further investigated.

In case you missed it

Read below to stay up to date on recent MD Anderson press releases across the spectrum of cancer research.

– 30 –


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.


Source link

]]>
https://parentraide-cancer.org/md-anderson-research-highlights-esmo-2021-sp/feed/ 0
Local family seeks support for research into childhood cancer treatment https://parentraide-cancer.org/local-family-seeks-support-for-research-into-childhood-cancer-treatment/ https://parentraide-cancer.org/local-family-seeks-support-for-research-into-childhood-cancer-treatment/#respond Fri, 17 Sep 2021 15:01:15 +0000 https://parentraide-cancer.org/local-family-seeks-support-for-research-into-childhood-cancer-treatment/ September is an important month for the community of families with their children who are battling childhood cancer. September – recognized as Childhood Cancer Awareness Month – is a time to show support and raise these families through prayer and, if possible, make a donation to an organization that supports cancer research in children. According […]]]>

September is an important month for the community of families with their children who are battling childhood cancer. September – recognized as Childhood Cancer Awareness Month – is a time to show support and raise these families through prayer and, if possible, make a donation to an organization that supports cancer research in children.

According to the American Childhood Cancer Organization, every three minutes a child is diagnosed with cancer around the world.

About 40,000 children are on active treatment at any given time.

The National Pediatric Cancer Foundation states that only 4% of the billions of dollars the government spends on cancer research each year goes to treating childhood cancer.

Every day, 43 children in the United States are expected to be diagnosed with cancer, with cancer being the leading cause of death from disease in children. Over 95% of childhood cancer survivors have significant health problems due to current treatment options.

Local child Journey Cummins has been cancer free for three and a half years. His scans remain clear with no sign of illness. Her parents pray over her body daily and several times throughout the day for continued healing.

“She is a real miracle. I will continue to recount his journey to share the conscience, but oh, I can’t wait to hear him tell his own story of God’s grace someday soon! said her mother, Tara Cummins.

The Cummins ask others to imagine a loved one with cancer – your child, grandchild, brother, sister, niece or nephew.

There aren’t many treatment options designed specifically to treat children, according to Cummins.

The only treatment options are adult therapy from the 1960s, with debilitating and long-lasting side effects. If children survive, they often do so with disabilities, with a 95% chance of developing chronic health problems, secondary cancers, cognitive impairments, and shortened lifespans due to harsh medical treatments, Cummins said.

This is the reality of families battling childhood cancer.

You can donate to support pediatric cancer research by donating to one of the Cummins family’s favorite organizations working on childhood cancer:

Nationalpcf.org

Stjude.org

Acco.org


Source link

]]>
https://parentraide-cancer.org/local-family-seeks-support-for-research-into-childhood-cancer-treatment/feed/ 0
Prognostic tests and their impact on breast cancer treatment https://parentraide-cancer.org/prognostic-tests-and-their-impact-on-breast-cancer-treatment/ https://parentraide-cancer.org/prognostic-tests-and-their-impact-on-breast-cancer-treatment/#respond Fri, 17 Sep 2021 05:21:00 +0000 https://parentraide-cancer.org/prognostic-tests-and-their-impact-on-breast-cancer-treatment/ Read the article Dr Aditi Thanky, consultant medical oncologist and Hematologist at Sterling Hospital in Rajkot talks about breast cancer treatment and the role of prognostic testing According to a report published by the WHO (World Health Organization), in 2020, 2.3 million women were diagnosed with breast cancer and 685,000 deaths worldwide. By the end […]]]>
Read the article

Dr Aditi Thanky, consultant medical oncologist and Hematologist at Sterling Hospital in Rajkot talks about breast cancer treatment and the role of prognostic testing

According to a report published by the WHO (World Health Organization), in 2020, 2.3 million women were diagnosed with breast cancer and 685,000 deaths worldwide. By the end of 2020, 7.8 million living women had been diagnosed with breast cancer in the past 5 years, making it the most common cancer in the world. Breast cancer is the most diagnosed cancer in women worldwide, accounting for 1 in 4 cancer cases. It is the most common cancer in both sexes and the leading cause of cancer death in women. In India, a woman is diagnosed with breast cancer every 4 minutes and a woman dies of breast cancer every 13 minutes, making it the most common cancer in Indian women.

Survival rates for breast cancer are very high when cancer is caught early and when treatment is available. Unfortunately, nearly 50% of breast cancer cases are diagnosed at an advanced stage (stage 3 and 4) in many low- and middle-income countries, such as India. The disease diagnosed at these stages is more difficult to treat and is usually incurable. The aggressiveness of breast cancer also depends on its type. TNBC (Triple Negative Breast Cancer) and HER2neu + are more aggressive than ER + / HER2neu- breast cancer which is relatively less aggressive.

Patients with ER + / HER2neu- breast cancer, if diagnosed at an early stage, have a good prognosis leading to a high survival rate. It has been observed and well documented in the literature that the majority of patients with early stage HR + / HER2neu- breast cancer have no benefit from chemotherapy. Not all patients respond the same to standard hormone therapy or chemotherapy. The prognosis of each patient with standard treatment is different. Typically, clinicians assess the prognosis of patients based on clinical factors such as tumor size, tumor grade, patient age, number. lymph nodes positive and status Ki-67, ER, PR, etc. Chemotherapy has a negative impact on the physical and mental health of patients undergoing treatment. It is primarily designed to target rapidly growing cancer cells. However, it also destroys healthy cells as it evolves, causing other debilitating side effects in patients.

Based on the risk factors mentioned above, patients are prescribed chemotherapy along with endocrine therapy. But these conventional clinical prognostic markers do not individually examine the disease holistically and therefore lack insight into how each patient responds to treatment more precisely.

What is a prognostic test?

A prognostic test predicts overall results after receiving standard therapy to treat breast cancer. They are different from diagnostic tests, which diagnose specific diseases and conditions. The difference between the two is that while a prognosis can be a guess as to the outcome of treatment or the occurrence of a medical event, a diagnosis actually identifies the problem and gives it a name. Prognostic tests predict a patient’s likelihood of developing disease recurrence or having a future medical event. Prognostic tests look for certain biomarkers in a patient’s body. Biomarkers are natural products in your body, such as antibodies, specific genes, gene expression patterns, or other biomarkers that can identify a particular disease or physiological process in an individual. Examples of biomarkers include everything from blood pressure and heart rate to basic metabolic studies and x-ray results to complex histological and genetic tests of blood and other tissues.

Early detection of breast cancer can save a patient from aggressive treatments such as chemotherapy, especially in ER + / HER2neu negative patients, and can lead to a better “quality of life” for the patient.

Patients diagnosed at an early stage may benefit from prognostic testing to determine the clinical outcome of disease and treatment. Prognostic tests assess the risk of cancer recurrence for each patient and allow doctors to tailor treatment for each individual, resulting in better quality of life and better clinical outcomes.

In some cases, patients may be identified as having a lower risk of cancer relapse based on clinical parameters or other prognostic markers such as Ki67, as judged by the clinician, which may not be precise about the future behavior of the patient. Cancer. The merit of the prognostic test is that it identifies the patient with higher risk of relapse based on the relevant characteristics of the cancer, which helps to optimize treatment for each patient. This ensures that the patient is not undertreated and saves the patient the risk of future cancer recurrences.

The importance of prognostic tests is evident from the fact that they are an essential part of breast cancer treatment as they are part of the main international cancer treatment guidelines such as the National Comprehensive Cancer Network (NCCN).

There are many prognostic tests available, but not all tests have proven their clinical utility and usefulness in Indian patients. The only prognostic test that has been developed and validated on Indian patients is the CanAssist breast test.

Breast cancer has a tremendous physical and emotional impact on a patient’s health. Taking the help of a prognostic test to determine the most suitable treatment option for a patient can bring us closer to a better and happy life for the patient who suffers from it.


Source link

]]>
https://parentraide-cancer.org/prognostic-tests-and-their-impact-on-breast-cancer-treatment/feed/ 0
SpaceX flight raised $ 130 million of its $ 200 million goal for pediatric cancer research https://parentraide-cancer.org/spacex-flight-raised-130-million-of-its-200-million-goal-for-pediatric-cancer-research/ https://parentraide-cancer.org/spacex-flight-raised-130-million-of-its-200-million-goal-for-pediatric-cancer-research/#respond Thu, 16 Sep 2021 20:25:00 +0000 https://parentraide-cancer.org/spacex-flight-raised-130-million-of-its-200-million-goal-for-pediatric-cancer-research/ The SpaceX flight taking four tourists on an alien escapade has also raised more than $ 130 million for childhood cancer research, and aims to raise $ 200 million in total. Jared Isaacman, the 38-year-old billionaire who paid for the space travel and commands the mission, pledged to donate $ 100 million to St. Jude […]]]>

The SpaceX flight taking four tourists on an alien escapade has also raised more than $ 130 million for childhood cancer research, and aims to raise $ 200 million in total.

Jared Isaacman, the 38-year-old billionaire who paid for the space travel and commands the mission, pledged to donate $ 100 million to St. Jude Children’s Research Hospital when he announced his plans for the flight in February. Isaacman has set a goal of using the theft ad, dubbed Inspiration4, to raise an additional $ 100 million for St. Jude, a hospital in Memphis, Tenn., Where children receive free cancer treatment.

Hours before liftoff on Wednesday, the fundraising campaign had grossed more than $ 31 million on top of Isaacman’s $ 100 million pledge, leaving around $ 69 million to be raised by the end of the campaign in February 2022, said Bruce Bobbins, spokesperson for St. Jude Children’s Research Hospital.

“We are confident that we will meet the target of $ 200 million,” Bobbins told MarketWatch.

Part of the money came from 72,000 participants in a raffle that offered the chance to win a seat on the flight. Participants were encouraged, but not required, to donate to St. Jude, according to contest rules, which estimated the retail value of the space flight at $ 2.21 million.

Crew member Chris Sembroski, a 42-year-old data engineer and U.S. Air Force veteran from Everett, Wash., Entered the lottery by donating. He didn’t win, but a friend did and gave him the slot, according to the Associated Press.

Isaacman and three teammates took off from the Kennedy Space Center in Cape Canaveral, Fla. On Wednesday night and were scheduled to land off the coast of Florida on Saturday.

Other members of the mission are Hayley Arceneaux, a childhood bone cancer survivor who was treated at St. Jude and now works there as a medical assistant, and Sian Proctor, a community college professor and pilot who won her award. seat through a competition sponsored by Isaacman’s company, Shift4 Payments FOUR,
+ 3.66%.

The Inspiration4 payload includes several items that will be auctioned off as part of the fundraising campaign, including an NFT from Kings of Leon performing a song; a ukulele that Sembroski will play in space; and four pilot’s watches designed by watchmaker IWC Schaffhausen.

St. Jude intends to use the $ 200 million to expand its reach, Bobbins said. “The goal is to expand research, find cures and cures, and expand the reach of St Jude’s efforts globally, because childhood cancer does not discriminate,” said said Bobbins. “It hits children of all origins, all ethnicities, all races, and it doesn’t just mean in the United States.”

When St. Jude was founded by actor Danny Thomas, star of the 1950s TV sit-com “Make Room for Daddy,” the childhood cancer survival rate was 20%; now it’s 80%, said Bobbins. “We want it to be 100%,” he said.

Isaacman became a billionaire in 2020 after Shift4 went public. His company has previously donated to St. Jude and he raised funds for the Make-A-Wish Foundation in 2008 and 2009 when he attempted to break a speed record around the world in a jet plane, Forbes . reported.

Isaacman did not disclose how much he paid for the space flight. His trip is the latest in a series of billionaire-funded space flights: Amazon AMZN,
+ 0.36%
founder Jeff Bezos ventured to the edge of space with his Blue Origin vehicle and Virgin Galactic’s SPCE,
+ 2.43%
Richard Branson reached an altitude of 53.5 miles.

The trips have sparked criticism of the value of wealthy people spending their resources on exploring personal space when that money could solve problems on Earth.

One of the frequently asked questions on the Inspiration4 website is: “Why spend so much money on space travel when there is such a desperate need here on earth?” ”

The answer: “Difficulties and suffering have unfortunately been present throughout the history of mankind, but no sooner can we turn away from the great need that surrounds us that we can suspend innovation and progress. . We have to find ways to do both. For starters, this is why we plan to raise significantly more funds for St. Jude Children’s Research Hospital than the cost of the mission, so that we can make an impact on today’s issues.

See also: Jeff Bezos hands over $ 100 million to Van Jones and José Andrés: “I have a little surprise for you”


Source link

]]>
https://parentraide-cancer.org/spacex-flight-raised-130-million-of-its-200-million-goal-for-pediatric-cancer-research/feed/ 0
FDA Approves IND Application for T-Cell Receptor Therapy to Treat Epithelial Cancers https://parentraide-cancer.org/fda-approves-ind-application-for-t-cell-receptor-therapy-to-treat-epithelial-cancers/ https://parentraide-cancer.org/fda-approves-ind-application-for-t-cell-receptor-therapy-to-treat-epithelial-cancers/#respond Wed, 15 Sep 2021 20:11:28 +0000 https://parentraide-cancer.org/fda-approves-ind-application-for-t-cell-receptor-therapy-to-treat-epithelial-cancers/ September 15, 2021 1 minute read ADD A SUBJECT TO E-MAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “data-action =” subscribe “> Subscribe We have not been able to process your request. Please try again later. […]]]>

September 15, 2021

1 minute read


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact customerservice@slakinc.com.

The FDA has cleared a new investigational drug application for T cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.

The agent is a genetically modified autologous T cell receptor therapy (TCR) that targets Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1), a cancer germ line antigen highly expressed in several epithelial tumors. These include gastrointestinal, lung, cervical and triple negative breast cancers.

3d image of T cells
Source: Adobe Stock.

Adoptive Cell Therapy was developed by NCI and acquired by T-Cure Bioscience under a worldwide exclusive license agreement in 2020.

The IND clearance will allow enrollment in a clinical trial that will evaluate KK-LC-1-led TCR therapy for adults with metastatic, relapsed or refractory epithelial cancers that have an expression greater than 25% of KK-LC- 1.

The single-center phase 1 clinical trial will be sponsored and conducted by NCI under a cooperative research and development agreement it has entered into with T-Cure. Principal investigators of the study include James L. Gulley, MD, PhD, head of the genitourinary malignancies branch at NCI, and Scott M. Norberg, D, research assistant physician in the genitourinary malignancies branch of the NCI.

“TCR T cell therapy is a promising new treatment modality that has demonstrated clinical activity in a subset of solid tumors,” Norberg said in a press release issued by T-Cure. “Our hope is that KK-LC-1 TCR-T cell therapy can be effective against common epithelial cancers, which account for 80-90% of all human malignancies. “

The primary objective of the dose escalation study is to determine the maximum tolerated dose of TCR TCR cells driven by KK-LC-1.

“We are delighted that NCI has obtained regulatory approval from the FDA to initiate a first human trial against a very important target in several solid tumors,” Gang Zeng, PhD, CEO of T-Cure said in the statement. “Dr. Norberg and Dr. Gulley have extensive experience in the development of new adoptive T cell therapies for cancer, and they will be invaluable as we move this program forward.


Source link

]]>
https://parentraide-cancer.org/fda-approves-ind-application-for-t-cell-receptor-therapy-to-treat-epithelial-cancers/feed/ 0
Council Rock student stays home amid cancer fight and mask warrant exemptions https://parentraide-cancer.org/council-rock-student-stays-home-amid-cancer-fight-and-mask-warrant-exemptions/ https://parentraide-cancer.org/council-rock-student-stays-home-amid-cancer-fight-and-mask-warrant-exemptions/#respond Tue, 14 Sep 2021 02:08:00 +0000 https://parentraide-cancer.org/council-rock-student-stays-home-amid-cancer-fight-and-mask-warrant-exemptions/ Carolyn Austin’s friends returned to school for an in-person learning at Goodnoe Elementary in the Council Rock School District on August 30. Much to her disappointment, Carolyn did not. “I miss playtime with my friends,” she said. The 9-year-old, who enjoys traveling and cooking, was diagnosed in June 2020 with acute lymphoblastic leukemia. Carolyn’s health […]]]>


Source link

]]>
https://parentraide-cancer.org/council-rock-student-stays-home-amid-cancer-fight-and-mask-warrant-exemptions/feed/ 0
TAR-200 / Cetrelimab under investigation in muscle-invasive bladder cancer https://parentraide-cancer.org/tar-200-cetrelimab-under-investigation-in-muscle-invasive-bladder-cancer/ https://parentraide-cancer.org/tar-200-cetrelimab-under-investigation-in-muscle-invasive-bladder-cancer/#respond Sat, 11 Sep 2021 14:50:09 +0000 https://parentraide-cancer.org/tar-200-cetrelimab-under-investigation-in-muscle-invasive-bladder-cancer/ “Patients with MIBC often have a poor prognosis and are at high risk of death. The standard treatment is platinum-based neoadjuvant chemotherapy for patients eligible for cisplatin, followed by radical cystectomy, which is associated with a high treatment load, ”said Williams, professor and head of the urology division of the medical branch of the University […]]]>

“Patients with MIBC often have a poor prognosis and are at high risk of death. The standard treatment is platinum-based neoadjuvant chemotherapy for patients eligible for cisplatin, followed by radical cystectomy, which is associated with a high treatment load, ”said Williams, professor and head of the urology division of the medical branch of the University of Texas. “Trimodal therapy is another bladder-sparing treatment, however, we have shown that over 50% of MIBC patients do not receive any definitive treatment. The combination of TAR-200 and cetrelimab is being studied to see if it can improve patient outcomes. “

Williams went on to say that TAR-200 is a new intravesical drug delivery system for sustained release of gemcitabine into the bladder, which increases dwell time and local drug dose. “Treatment with TAR-200 has demonstrated early clinical benefit with favorable toxicity in patients with MIBC. Cetrelimab is an investigational immunoglobulin g4 antibody that targets the PD-1 receptor, blocking PD-L1 and PD-L2 signaling.

SunRISe-2 is a prospective, multicenter, open-label, randomized phase 3 study evaluating the efficacy and safety of intravesical TAR-200 plus systemic cetrelimab compared to chemoradiation in participants with MIBC. To be eligible, adults must have an ECOG Performance Index of 0 to 2, and a histologically proven diagnosis, cT2 to T4a, N0, M0 MIBC, and they must be ineligible or refuse radical cystectomy.

Researchers opened recruitment at 272 sites around the world in December 2020 and hope to recruit 550 patients. Participants will be stratified based on results of transurethral resection of bladder tumors screening (visibly complete vs incomplete) and tumor screening stage (T0 vs Ta / T1 / Tis vs T2-T4a).

Participants in arm 1 will receive TAR-200 intravesically every 3 weeks for the first 18 weeks. From week 24, the dosage will drop to every 12 weeks up to 144 weeks. Cetrelimab will be administered every 3 weeks until month 18. Patients in arm 2 will receive standard chemoradiotherapy with cisplatin or gemcitabine for up to 6 weeks, plus the investigator’s choice of conventional hypofractionated chemotherapy.

Primary endpoint is intact bladder event-free survival (BI-EFS) defined as the time from randomization to the first BI-EFS event, including histologically proven MIBC, clinical evidence of lymph node or metastatic disease according to RECIST 1.1, radical cystectomy or death.

Investigators will perform a primary assessment of disease in both arms at week 18. They will perform axial imaging and cystoscopy at week 24, then every 12 weeks until the second year of the study, then every year. the 24 weeks until the fifth year of the study.

The main secondary endpoints include metastasis-free survival, overall survival, overall response rate at 18 weeks, and safety and tolerability. Exploratory endpoints include assessments of cancer-specific survival, time to symptomatic progression, pharmacokinetics, immunogenicity, health-related quality of life, resource utilization health and biomarkers.

MIBC is a potentially fatal disease, but many patients do not receive the aggressive curative treatment recommended. The standard of care is radical cystectomy with pelvic lymphadenectomy or chemoradiation, and the addition of platinum-based neoadjuvant chemotherapy improves survival outcomes.2 However, previous data shows that neoadjuvant chemotherapy is underused, especially in the elderly and in groups with low socioeconomic status.3

In April 2018, the FDA granted Fast Track designation to TAR-200 for the treatment of patients with organ-confined or locally advanced MIBC who are not eligible for curative treatment.4

In 2019, researchers initiated a phase 1b clinical trial (NCT03518320) evaluating TAR-200 in combination with nivolumab (Opdivo) for safety, tolerability and preliminary efficacy in patients with MIBC. The open, multi-center, single-arm study will enroll up to 25 patients who are scheduled to undergo radical cystectomy. Prior to radical cystectomy, patients will receive both TAR-200 and nivolumab on day 1 of 4 consecutive 21-day dosing cycles.5

The references

  1. Williams SB, Curtie C, Keegan KA et al. SunRISe-2: A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concomitant chemoradiotherapy in participants with muscle invasive urothelial bladder carcinoma. Presented at the 2021 American Urological Association Annual Meeting; September 10-13, 2021; virtual. Abstract MP13-17.
  2. Huo J, Ray-Zack MD, Shan Y, et al. Patterns of discernment and quality of neoadjuvant chemotherapy use in patients with muscle invasive bladder cancer. Eur Urol Oncol. 2019; 2 (5): 497-504. doi: 10.1016 / j.euo.2018.07.009
  3. Gray PJ, Fedewa SA, Shipley WU, et al. Eur Urol. 2013; 63 (5): 823-829. doi: 10.1016 / j.eururo.2012.11.015
  4. TARIS Bio. The US FDA grants TARIS Fast Track designation for TAR-200 (GemRIS) in muscle invasive bladder cancer. Press release. April 3, 2018. Accessed September 11, 2021. https://bwnews.pr/2XaB3ci
  5. TARIS Bio. TARIS is initiating a clinical trial of TAR-200 in combination with Opdivo (nivolumab) for patients with muscle invasive bladder cancer. Press release. July 10, 2019. Accessed September 11, 2021. https://prn.to/3k4afn2


Source link

]]>
https://parentraide-cancer.org/tar-200-cetrelimab-under-investigation-in-muscle-invasive-bladder-cancer/feed/ 0
HRT and breast cancer: risk, prevention and alternatives https://parentraide-cancer.org/hrt-and-breast-cancer-risk-prevention-and-alternatives/ https://parentraide-cancer.org/hrt-and-breast-cancer-risk-prevention-and-alternatives/#respond Wed, 08 Sep 2021 17:19:20 +0000 https://parentraide-cancer.org/hrt-and-breast-cancer-risk-prevention-and-alternatives/ Hormone replacement therapy (HRT) is a treatment option for symptoms associated with menopause. Although it can increase the risk of breast cancer, this risk is low and will return to average after stopping HRT. A person should discuss the benefits and risks of HRT with a healthcare professional. The risk of breast cancer can decrease […]]]>

Hormone replacement therapy (HRT) is a treatment option for symptoms associated with menopause. Although it can increase the risk of breast cancer, this risk is low and will return to average after stopping HRT. A person should discuss the benefits and risks of HRT with a healthcare professional.

The risk of breast cancer can decrease dramatically after a person stops using HRT. However, the time it takes is not final.

The risk of breast cancer also depends on the type of HRT a person is taking.

There are two types of HRT: combined HRT, which contains both estrogen and progesterone, and estrogen-only HRT.

The following article explains how HRT increases breast cancer risk, ways to prevent breast cancer, and potential alternatives to HRT.

BreastCancer.org notes that the number of people using HRT has declined since research in 2002 initially found a link between HRT and breast cancer.

A Study 2020 who reviewed a large database of work on the link between HRT and breast cancer confirmed the results of previous studies.

The researchers noted that prolonged or long-term use of combined therapies with progesterone and estrogen or estrogen alone significantly increased the risk of breast cancer.

They found that the level of risk may differ between types of HRT.

They also said that HRT using estradiol-dydrogesterone had the lowest risk of developing breast cancer and the risk seemed to decrease after stopping HRT use.

Breast cancer now, a UK charity, notes that the risk of developing breast cancer in someone aged 50 to 96 is as follows:

  • 63 in 1,000 women who have never taken HRT
  • 83 in 1,000 women who use combined HRT for 5 years
  • 68 in 1,000 women who use estrogen-only HRT for 5 years

Estrogen and progesterone combined may have the highest risk factor for any type of HRT. According to BreastCancer.org, the risk of developing breast cancer increases by 75% in people taking combined HRT.

The organization also noted that combined HRT increases the chances that a healthcare professional can diagnose a person’s breast cancer at a later stage, which increases the likelihood of death.

According to Research 2020, the risk of breast cancer increases the longer a person takes HRT. However, it also decreases significantly after a person stops HRT.

American Cancer Society (ACS) Says Breast Cancer Risk Is Returning to Average 3 years after a person stops combined HRT.

However, researchers in the 2020 study found that the risk decreased after 5 years for medroxyprogesterone and 10 years for levonorgestrel, which are types of progesterone.

Combination HRT is also linked to breast density, which can make it more difficult to locate cancer on a mammogram. Breast density is a term that describes the amount of dense tissue relative to fatty tissue in a person’s breast. Dense tissue is more fibrous than fatty tissue.

HRT containing estrogen alone may also increase a person’s risk of developing breast cancer. However, this can only increase the risk after 10 years of continuous use.

The Study 2020 showed that the increased risk after taking estrogen-only HRT was small, but it also confirmed that the risk increased with length of use. They also noted that the risk decreased even more the longer it had been since a person had stopped using HRT.

A person who has had or has breast cancer should not take HRT. Instead, they should talk to a doctor about the alternative options.

According to ACS, using HRT after breast cancer may increase the risk of recurrence or development of new tumors.

The American College of Obstetricians and Gynecologists notes that first-line choices for managing menopause symptoms in people during or after their breast cancer treatment include non-hormonal approaches.

These include moisturizers, topical anesthetics, and lubricants to treat vaginal symptoms.

Those with a history of estrogen-dependent breast cancer may use vaginal estrogen therapy if they don’t respond to non-hormonal approaches. Vaginal estrogen therapy delivers low doses of hormones.

A 2019 article in the journal Breast Cancer Archives states that there are no guidelines on the safety of using HRT in people with a family history of breast cancer.

A Systematic review from 2021 notes that HRT has no relevant effect on the risk of cancer in people carrying the BRCA gene.

Another to study of 2018 found that using estrogen after surgery to remove the ovaries does not increase the risk of breast cancer in people with the BRCA1 gene. However, they also note that more research is needed on the effect of HRT containing progesterone.

Breast cancer now suggests that a person should talk to a doctor before using HRT if they have inherited a breast cancer gene, such as BRCA1 or BRCA2.

If a person decides to take HRT, they may request a lower dose formula. They can also discuss with a doctor how to take it as quickly as possible.

BreastCancer.org Note that there are things there are things that people can do to reduce their risk of developing breast cancer, whether or not they are using HRT.

They recommend a person:

  • regular exercise
  • eating foods rich in nutrients
  • stop smoking, if necessary
  • limit their alcohol consumption

It is also important to achieve and maintain a healthy weight. This is because having more fatty tissue can increase a person’s estrogen levels and as a result, increase the chances to develop breast cancer.

The ACS adds that a person at higher risk of breast cancer may benefit from additional measures, such as:

  • close surveillance
  • ask for genetic testing and counseling
  • get preventive surgery

For people at high risk of developing breast cancer, an oncologist can prescribe drugs such as tamoxifen and raloxifene.

The benefits of taking HRT may vary from person to person. Some people decide that the benefits outweigh the risks.

HRT can help relieve symptoms of menopause. It can also help reduce the risk of developing osteoporosis.

A person should discuss the benefits and risks with a healthcare professional before deciding whether HRT is right for them.

If a person decides to take HRT, they should attend all of their breast cancer screening appointments.

Some companies produce bioidentical hormone therapy. Bioidentical hormones are theoretically derived from plants.

Many companies claim that their bioidentical hormonal products are a safer alternative to conventional HRT, which may consist of synthetic hormones. However, the Food and Drug Administration (FDA) does not regulate these supplements.

In addition, the higher risk of breast cancer is same for bio-identical hormones as for synthetic hormones. Synthetic hormones are made in the laboratory and chemically identical to those in the body.

A person should speak with a doctor about the risks of HRT, especially if they already have a higher risk of developing breast cancer. Their doctor will likely suggest a different treatment plan that doesn’t involve HRT.

According to Women’s health office, a person may not need formal treatment for their menopause symptoms. When they do, some treatments that don’t involve HRT may include:

  • over-the-counter or prescription products to treat vaginal dryness or discomfort, such as vaginal lubricants
  • natural remedies, such as soybeans or red clover
  • mind and body practices, such as yoga or acupuncture

Exercise can help improve mood and sleep, and reduce hot flashes. A person should also avoid spicy foods, caffeine, and alcohol as they can cause hot flashes.

A person can learn more about natural remedies to help manage the symptoms here.

Medications

A person can also take the following medications:

  • Clonidine: It is a drug that treats high blood pressure. It may be able to reduce hot flashes and night sweats. However, it can cause side effects including low blood pressure, dry mouth, depression, constipation, and drowsiness. A person can take this medicine for 2-4 weeks to see if it’s effective. If not, a person should stop taking it.
  • Antidepressants: Examples include venlafaxine and citalopram. These may be able to treat hot flashes. Side effects can include nausea, dizziness, trouble sleeping, and anxiety. They can also cause low libido and weight gain.
  • Tibolone: Tibolone is similar to combined HRT. It is a synthetic hormone that those who have a uterus can take. However, it contains both estrogen and progesterone, so if a person is unable to take HRT due to medical conditions, they will not be allowed to take this drug.

HRT increases the risk of breast cancer. The risk tends to increase with combination therapies as well as with long term use.

A person who has had breast cancer or has a family history of the disease should see a doctor before using HRT for their menopausal symptoms. A doctor can discuss other solutions which may include over-the-counter and prescription medications, as well as natural and holistic therapies.


Source link

]]>
https://parentraide-cancer.org/hrt-and-breast-cancer-risk-prevention-and-alternatives/feed/ 0